#	Pagina
attuale pagina	/open-h2020/projects/207443/index.html

Opendata, web and dolomites

IMMUNOSABR SIGNED

Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

IMMUNOSABR project word cloud

Explore the words cloud of the IMMUNOSABR project. It provides you a very rough idea of what is the project "IMMUNOSABR" about.

lung packages geared palliative standard opening 6wde6rkrika immunological mutation gov animation explaining site anti efficacy le drug nsclc ablative therapy stereotactic direct commercial limited abscopal monitoring biomarker techniques clinicaltrials modal translate blood immunosabr intent care synergistic treating form combined watch powerful randomised bi relies sites proof irradiated l19 curative il2 personalised cell radiation treatment small youtu metastatic obtaining paradigm effect invasive imaging clinical gather disease sabr oligo benefit patients cancer immunotherapy precision tissue cytotoxic nct02735850 distance strategy tumour immunocytokine https multicentre radiotherapy unless spur actionable complemented

Project "IMMUNOSABR" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.immunosabr.info/
Total cost	5˙994˙176 €
EC max contribution	5˙994˙176 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT MAASTRICHT UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	coordinator	1˙914˙531.00
2	DANMARKS TEKNISKE UNIVERSITET DANMARKS TEKNISKE UNIVERSITET Organization address address: ANKER ENGELUNDSVEJ 1 BYGNING 101 A city: KGS LYNGBY postcode: 2800 website: www.dtu.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KGS LYNGBY)	participant	1˙078˙407.00
3	PHILOGEN SPA PHILOGEN SPA Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.philogen.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	726˙250.00
4	HEALTH INNOVATION VENTURES BV HEALTH INNOVATION VENTURES BV Organization address address: OXFORDLAAN 55 BIOPARTNER GEBOUW city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	434˙250.00
5	PT THERAGNOSTIC BV PT THERAGNOSTIC BV Organization address address: OXFORDLAAN 55 BIOPARTNER BUILDING city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	312˙500.00
6	ACADEMISCH ZIEKENHUIS MAASTRICHT ACADEMISCH ZIEKENHUIS MAASTRICHT Organization address address: P DEBYELAAN 25 city: MAASTRICHT postcode: 6229 HX website: www.unimaasnl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	participant	181˙675.00
7	EBERHARD KARLS UNIVERSITAET TUEBINGEN EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 website: www.uni-tuebingen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	165˙050.00
8	KATHOLIEKE UNIVERSITEIT LEUVEN KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: OUDE MARKT 13 city: LEUVEN postcode: 3000 website: www.kuleuven.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LEUVEN)	participant	165˙050.00
9	CENTRE OSCAR LAMBRET CENTRE OSCAR LAMBRET Organization address address: RUE FREDERIC COMBEMALE 3 city: LILLE postcode: 59020 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	participant	115˙175.00
10	CLINIQUES UNIVERSITAIRES SAINT-LUC CLINIQUES UNIVERSITAIRES SAINT-LUC Organization address address: AVENUE HIPPOCRATE 10 city: BRUXELLES postcode: 1200 website: http://www.saintluc.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	115˙175.00
11	STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX website: www.nki.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	115˙175.00
12	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	115˙175.00
13	TECHNISCHE UNIVERSITAET DRESDEN TECHNISCHE UNIVERSITAET DRESDEN Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 website: http://www.tu-dresden.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	115˙175.00
14	UNIVERSITA CATTOLICA DEL SACRO CUORE UNIVERSITA CATTOLICA DEL SACRO CUORE Organization address address: Largo Agostino Gemelli 1 city: MILANO postcode: 20123 website: www.unicattolica.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	115˙175.00
15	UNIVERSITAIR ZIEKENHUIS GENT UNIVERSITAIR ZIEKENHUIS GENT Organization address address: CORNEEL HEYMANSLAAN 10 city: GENT postcode: 9000 website: http://www.uzgent.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GENT)	participant	115˙175.00
16	UNIVERSITY COLLEGE LONDON UNIVERSITY COLLEGE LONDON Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	115˙175.00
17	EUROPEAN CANCER PATIENT COALITION EUROPEAN CANCER PATIENT COALITION Organization address address: RUE MONTOYER 40 city: BRUXELLES postcode: 1000 website: www.ecpc-online.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	95˙062.00

Map

Project objective

IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA).

Palliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (≤10 sites, WHO 0-1: “oligo”) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC.

IMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.

Publications

List of publications.
year	authors and title	journal	last update
2018	Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink, Philippe Lambin 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) â€“ A prospective externally validated study published pages: e0192859, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0192859	PLOS ONE 13/3	2020-04-08
2018	David A. Jaffray, Shiva Das, Paula M. Jacobs, Robert Jeraj, Philippe Lambin How Advances in Imaging Will Affect Precision Radiation Oncology published pages: 292-298, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2018.01.047	International Journal of Radiation OncologyBiologyPhysics 101/2	2020-04-08
2018	Ralph TH Leijenaar, Marta Bogowicz, Arthur Jochems, Frank JP Hoebers, Frederik WR Wesseling, Sophie H Huang, Biu Chan, John N Waldron, Brian O\'Sullivan, Derek Rietveld, C Rene Leemans, Ruud H Brakenhoff, Oliver Riesterer, Stephanie Tanadini-Lang, Matthias Guckenberger, Kristian Ikenberg, Philippe Lambin Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study published pages: 20170498, ISSN: 0007-1285, DOI: 10.1259/bjr.20170498	The British Journal of Radiology	2020-04-08
2018	DaniÃ«lle B.P. Eekers, Esther N. Pijnappel, Olaf E.M.G. Schijns, Albert Colon, Ann Hoeben, Jaap D. Zindler, Alida A. Postma, Aswin L. Hoffmann, Philippe Lambin, Esther G.C. Troost Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review published pages: 83-92, ISSN: 1059-1311, DOI: 10.1016/j.seizure.2018.01.009	Seizure 55	2020-04-08
2018	Richard P. Baum, Harshad R. Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C. Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter HÃ¶rsch Results and adverse events of personalized peptide receptor radionuclide therapy with ⁹⁰Yttrium and ¹⁷⁷Lutetium in 1048 patients with neuroendocrine neoplasms published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.24524	Oncotarget 9/24	2020-04-08
2018	Davide Cusumano, Nicola Dinapoli, Luca Boldrini, Giuditta Chiloiro, Roberto Gatta, Carlotta Masciocchi, Jacopo Lenkowicz, Calogero CasÃ , Andrea Damiani, Luigi Azario, Johan Van Soest, Andre Dekker, Philippe Lambin, Marco De Spirito, Vincenzo Valentini Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer published pages: 286-295, ISSN: 0033-8362, DOI: 10.1007/s11547-017-0838-3	La radiologia medica 123/4	2020-04-08
2018	SeÃ¡n Walsh, Erik Roelofs, Peter Kuess, Yvonka van Wijk, Ben Vanneste, Andre Dekker, Philippe Lambin, Bleddyn Jones, Dietmar Georg, Frank Verhaegen Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability published pages: 55, ISSN: 2072-6694, DOI: 10.3390/cancers10020055	Cancers 10/2	2020-04-08
2017	Ana Ureba, Emely Lindblom, Alexandru Dasu, Johan Uhrdin, Aniek J. G. Even, Wouter van Elmpt, Philippe Lambin, Peter WersÃ¤ll, Iuliana Toma-Dasu Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription published pages: 485-490, ISSN: 0284-186X, DOI: 10.1080/0284186X.2017.1400177	Acta Oncologica 57/4	2020-04-08
2018	Sena Apeke, Laurent Gaubert, Nicolas Boussion, Philippe Lambin, Dimitris Visvikis, Vincent Rodin, Pascal Redou Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy published pages: 871-880, ISSN: 0278-0062, DOI: 10.1109/TMI.2017.2771379	IEEE Transactions on Medical Imaging 37/4	2020-04-08
2018	DaniÃ«lle B.P. Eekers, Lieke in \'t Ven, Sabine Deprez, Linda Jacobi, Erik Roelofs, Ann Hoeben, Philippe Lambin, Dirk de Ruysscher, Esther G.C. Troost The posterior cerebellum, a new organ at risk? published pages: 22-26, ISSN: 2405-6308, DOI: 10.1016/j.ctro.2017.11.010	Clinical and Translational Radiation Oncology 8	2020-04-08
2017	Arthur Jochems, Issam El-Naqa, Marc Kessler, Charles S. Mayo, Shruti Jolly, Martha Matuszak, Corinne Faivre-Finn, Gareth Price, Lois Holloway, Shalini Vinod, Matthew Field, Mohamed Samir Barakat, David Thwaites, Dirk de Ruysscher, Andre Dekker, Philippe Lambin A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy published pages: 226-230, ISSN: 0284-186X, DOI: 10.1080/0284186X.2017.1385842	Acta Oncologica 57/2	2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOSABR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOSABR" are provided by the European Opendata Portal: CORDIS opendata.